Printer Friendly

Nanosphere reports encouraging study data for Verigene gram-positive blood culture test.

M2 PHARMA-July 3, 2013-Nanosphere reports encouraging study data for Verigene gram-positive blood culture test(C)2013 M2 COMMUNICATIONS

3 July 2013 - US molecular diagnostics system developer Nanosphere Inc (NASDAQ:NSPH) reported Tuesday encouraging results for the diagnostic accuracy and potential clinical impact of its FDA-approved Verigene Gram-Positive Blood Culture (BC-GP) Test.

The findings from a prospective, multi-centre study showed that the test can simultaneously detect and identify Staphylococcus aureus and 11 other gram-positive bacterial gene targets that cause bloodstream infections and three genetic resistance determinants, namely the mecA, vanA and vanB genes, directly from positive blood culture media.

Furthermore, a retrospective analysis of turn-around time demonstrated that the assay managed to identify methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) species about 42 hours earlier compared with similar methods.

The study results were included in the journal PLOS Medicine, published by the Public Library of Science.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 3, 2013
Previous Article:ArthroCare Corp buys USD45m ENTrigue Surgical Inc in all cash transaction.
Next Article:Journal of Clinical Oncology publishes study data for NanoStringa[euro](tm)s Prosigna Breast Cancer Assay.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters